Moderna Launches Caperna LLC, Its Fourth Venture, to Develop Personalized Cancer Vaccines

On October 22, 2015 Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics, reported the launch of Caperna LLC, the fourth Moderna venture, which will focus exclusively on the advancement of personalized cancer vaccines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Caperna will apply Moderna’s mRNA vaccine technology to the field of cancer vaccines, building on advances in recent years in cancer immunotherapy, including the availability of checkpoint inhibitors and the ability to rapidly determine individual patient mutations. Caperna will develop personalized cancer vaccines that encode a patient’s specific neoepitopes, utilizing Moderna’s unique infrastructure to manufacture within weeks small batches of vaccines tailored to each patient.

Substantial efforts at Moderna’s infectious disease venture Valera have demonstrated preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, which has led to the nomination of several viral vaccine development candidates. These advancements have spurred the formation of Caperna and the pursuit of vaccine development for the treatment of cancer.

Tal Zaks, M.D., Ph.D., Chief Medical Officer of Moderna, who was formerly Senior Vice President and Head of Global Oncology at Sanofi, will serve as Interim President of Caperna. Nicholas Valiante, Ph.D., who recently joined Moderna from Novartis Vaccines where he was Global Head of Immunology & Immunotherapy Research, will serve as Vice President and Head of Personalized Vaccine Sciences.

"With such a potent vaccine platform and a manufacturing process that lends itself directly to rapid production of patient-specific therapies, we believe Moderna’s mRNA approach will offer distinct advantages in the development of new cancer therapies," said Dr. Zaks. "We expect our ability to specifically activate and direct the immune system will synergize with checkpoint inhibitor therapies like PD-1 antibodies."

"What is perhaps most exciting about our approach and our core protein expression platform is its potential to leverage a broad spectrum of leading-edge drug modalities," said Stéphane Bancel, Chief Executive Officer of Moderna. "Caperna is an important example of Moderna’s unique ability to rapidly translate our ever-evolving understanding of mRNA into new therapeutic opportunities that have the potential to impact and change numerous lives. Caperna will be backed by Moderna’s $840 million of cash on hand."

Onkaido, Moderna’s initial oncology venture, remains focused on the development of mRNA-based therapeutics for oncology in areas outside of the personalized cancer vaccine effort at Caperna.

Knowledge-Based Software Can Significantly Expedite Creation of High-Quality Radiotherapy Treatment Plans for Precise Tumor Targeting

On October 22, 2015 Varian Medical Systems reported that studies presented earlier this week at the 2015 annual meeting of the American Society for Radiation Oncology (ASTRO) confirmed that knowledge-based treatment planning software can dramatically improve the speed and quality of cancer care (Press release, Varian Medical Systems, OCT 22, 2015, View Source [SID:1234507766]). One award-winning study by a team using RapidPlan software from Varian Medical Systems (NYSE: VAR) showed that radiotherapy treatment planning for cervical cancer can be done in minutes rather than hours, with superior quality.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In a presentation that was named among the "Best of ASTRO" and won the Basic/ Translational Science Abstract Award in the physics category, Nan Li, PhD, postdoctoral fellow at the University of California, San Diego (UCSD), and her team1 reported on their use of a RapidPlan model that was based on a refined sample of 86 previously-treated cervical cancer cases. They found that treatment planning time for intensity-modulated radiation therapy took an average of 6.85 minutes.[1] According to Kevin Moore, PhD, senior author on the study, UCSD dosimetrists estimate that manual GYN planning would require anywhere from 2-6 hours of optimization. "The use of knowledge-based planning represents a considerable time savings and reduced personnel costs," he said.

RapidPlan also improved plan quality compared to conventionally generated plans by minimizing the impact on normal surrounding tissues. "With both dramatic efficiency gains and improved normal tissue sparing, the final automated planning module was validated as both a clinical trial quality control system and a valuable tool for high-quality clinical planning in cervical cancer," observed Li.

Moore and his physician colleagues from UCSD also described work where stereotactic radiosurgery (SRS) treatment plans created using automated knowledge-based planning algorithms that they developed were set against manually-created clinical plans in a blinded comparison study.[2]

"In a clear majority of the cases, automated SRS planning demonstrated superior or equivalent plan quality to existing manual planning processes," Moore said. "Further refinement of algorithms to balance the complex clinical tradeoffs for high-priority organs-at-risk . . . will likely improve this technique further."

Researchers from Duke University evaluated a "rapid learning approach" in which clinicians "train" the RapidPlan tool by establishing a base knowledge model and continuously evaluate and update this knowledge model using subsequent cases. In their research on pelvic cancer cases, Jackie Wu, PhD, professor of radiation oncology, and her colleagues compared the RapidPlan rapid learning approach to the batch training method: knowledge modeling based on a static set of training cases.[3]

"The rapid learning approach is able to learn knowledge models for multiple cancer types in the pelvic region with comparable accuracy to the batch training method and with improved efficiency," Dr. Wu said. "This approach will facilitate the implementation of the knowledge based radiation therapy planning in clinics."

Knowledge-based planning enables clinicians to extract information from past clinical experience and use it to generate mathematical models that expedite the creation of new treatment plans. The software helps the planner quickly generate a new treatment plan that achieves the physician’s tumor coverage and normal tissue sparing goals, greatly reducing the need for time-consuming, manual trial-and-error processes while still optimizing quality.

"Varian’s RapidPlan software is a very robust knowledge-based planning solution that was developed to help clinical teams enhance quality, consistency, and efficiency in radiotherapy treatment planning," said Kolleen Kennedy, president of Varian Oncology Systems. "We are gratified to see research being conducted and presented, affirming the value of this tool for enhancing access to quality cancer treatment around the world. With the publication in the Lancet, last month, of a special report on the need to expand global access to radiotherapy, Varian is pleased to be offering tools like RapidPlan designed to improve utilization of radiotherapy around the world." [4]

FDA approves new treatment for advanced pancreatic cancer

On October 22, 2015 The U.S. Food and Drug Administration reported it approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy (Press release, , OCT 22, 2015, View Source [SID:1234507767]).
According to the National Cancer Institute, there will be 48,960 new cases of pancreatic cancer diagnosed in the U.S. in 2015, and nearly the same number of deaths caused by the disease (40,560). Pancreatic cancer can be difficult to diagnose early and treatment options are limited, especially when the disease has spread to other parts of the body (metastatic disease) and surgery to remove the tumor is not possible.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Many FDA staff who review drug applications are clinicians as well, so it’s especially rewarding when we are able to expedite access to new treatments for patients with unmet needs," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. "By using the Priority Review designation for the application for Onivyde, patients will have earlier access to a drug that helps extend survival."

The FDA granted Priority Review and orphan drug designations for Onivyde. Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition. Orphan drug designation provides incentives such as tax credits, user fee waivers, and eligibility for orphan drug exclusivity to assist and encourage the development of drugs for rare diseases.

The effectiveness of Onivyde was demonstrated in a three-arm, randomized, open label study of 417 patients with metastatic pancreatic adenocarcinoma whose cancer had grown after receiving the chemotherapeutic drug gemcitabine or a gemcitabine-based therapy. The study was designed to determine whether patients receiving Onivyde plus fluorouracil/leucovorin or Onivyde alone lived longer than those receiving fluorouracil/leucovorin. Patients treated with Onivyde plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin. There was no survival improvement for those who received only Onivyde compared to those who received fluorouracil/leucovorin.

In addition, patients receiving Onivyde plus fluorouracil/leucovorin had a delay in the amount of time to tumor growth compared to those who received fluorouracil/leucovorin. The average time for those receiving Onivyde plus fluorouracil/leucovorin was 3.1 months compared to 1.5 months for those receiving fluorouracil/leucovorin.

The safety of Onivyde was evaluated in 398 patients who received either Onivyde with fluorouracil/leucovorin, Onivyde alone or fluorouracil/leucovorin. The most common side effects of treatment with Onivyde included diarrhea, fatigue, vomiting, nausea, decreased appetite, inflammation in the mouth (stomatitis) and fever (pyrexia). Onivyde was also found to result in low counts of infection-fighting cells (lymphopenia and neutropenia). Death due to sepsis following neutropenia has been reported in patients treated with Onivyde.

The labeling for Onivyde includes a boxed warning to alert health care professionals about the risks of severe neutropenia and diarrhea. Onivyde is not approved for use as a single agent for the treatment of patients with metastatic pancreatic cancer.

Onivyde is marketed by Merrimack Pharmaceuticals Inc. of Cambridge, Massachusetts.

MabVax Therapeutics HuMab 5B1 Antibody Featured in Five Presentations at the World Molecular Imaging Congress

On October 21, 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) a clinical-stage oncology drug development company reported its antibody, HuMab 5B1 was featured in five separate presentations at the recently held World Molecular Imaging Congress (WMIC) in September (Press release, MabVax, OCT 21, 2015, View Source [SID:1234507749]). The presentations were made by investigators from the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) describing the novel use of MabVax’s lead antibody as a PET imaging agent and a radioimmunotherapy agent targeting pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following is a summary of the key points from the presentations;

Jacob Houghton, Ph.D. presented data demonstrating that the HuMab 5B1 antibody based PET imaging agent could be useful even in the context of shed antigen. Most pancreatic cancer patients shed an antigen called CA 19-9, which is a validated biomarker for pancreatic cancer. This same target is overexpressed on the surface of pancreatic cancer cells in more than 80% of patients and is the target for the HuMab 5B1 antibody. In animal models of pancreatic cancer, the experiments examined adding small amounts of HuMab 5B1 antibody not labeled with radiotracer to "soak up" excess circulating antigen. By varying the amount of unlabeled antibody and the time before injection of the HuMab 5B1 PET agent, Dr. Houghton was able to determine the variables required to optimize PET images. However, regardless of time of administration or amount of non-radiotracer antibody administered, images consistently illuminated the cancer.

Ryan Lanning, M.D., Ph.D. presented the results of experiments using the HuMab 5B1 antibody as a radioimmunotherapy agent against pancreatic cancer. Dr. Lanning conjugated the HuMab 5B1 antibody to two different and commonly used radiometals in radioimmunotherapy and tested them in animal models of pancreatic cancer. He varied the dose administered as well as examined the impact of combining the 5B1 radioimmunotherapy agent with chemotherapy. Both the radioimmunotherapy conjugates demonstrated significant tumor toxicity and excellent tumor localization potentially minimizing toxic adverse effects. Subsequent to administration of the radioimmunotherapy agent, follow-on administration of the HuMab 5B1 PET product continued to demonstrate sustained tumor selectivity allowing for administration of additional antibody based therapeutic or diagnostic agents.
Jan-Philip Meyer, Ph.D. and Jacob Houghton, Ph.D. each presented research using pretargeting as an effective way to combine the favorable pharmaocokinetic properties of radiolabeled small molecules with short half-lives with the affinity and specificity of the HuMab 5B1 antibody. Using different linking technologies and different radiotracers each investigator reported very good PET images with very favorable tumor-to-background activity ratios. The objective of both sets of experiments was to demonstrate methods that could be used to reduce the exposure of patients to excess radiation when undergoing PET imaging. Both investigators were able to achieve that objective even in the presence of shed antigen.

Dalya Abdel-Atti presented research showing that using a HuMab 5B1 based PET imaging agent produced high-quality images in a pancreatic cancer murine organoid model even in the presence of shed antigen. A central drawback of many animal models of disease is that they aren’t always predictive of the results obtained in actual patients. The murine organoid model is a newly developed model that more faithfully replicates metastatic pancreatic cancer in patients. The investigators at MSK believe that this is the first time PET imaging has been successfully performed in a murine organoid model of pancreatic cancer.

David Hansen, CEO of MabVax commented "These investigators need to be commended for the pioneering work they presented and the important steps forward they have made in building capabilities to diagnose and treat a very difficult cancer. MabVax is grateful to Jason S. Lewis, Ph.D. and his team for their pioneering work done with our HuMab 5B1 antibody. All of these results are helpful steps forward in advancing the collective knowledge of this devastating cancer and provide valuable insights for MabVax as we continue to develop HuMab 5B1 as both a therapeutic and diagnostic product."

About HuMab 5B1

The fully human antibody HuMab 5B1 was recovered from patients undergoing cancer vaccine treatment at Memorial Sloan Kettering Cancer Center. The HuMab 5B1 has demonstrated high specificity, affinity, and lack of cross-reactivity with similar antigens. The antibody has also shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon, and small cell lung cancers. Ongoing toxicology results continue to demonstrate an acceptable profile in acute and repeat dose studies in animals. MabVax plans to initiate two complementary Phase I clinical trials in the first quarter of 2016. One clinical trial is aimed at determining the safety and potential utility of HuMab 5B1 as a therapeutic agent in subjects with metastatic pancreatic cancer. The second clinical trial is aimed at demonstrating the utility of 89Zr-HuMab 5B1, the Company’s radio-labeled HuMab 5B1 antibody, as a next-generation PET imaging agent for the diagnosis, staging, and management of pancreatic cancer.

Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma

On October 21, 2015 Novartis reported that it is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation (Press release, Novartis, OCT 21, 2015, View Source;year=2015 [SID:1234507781]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With four candidates currently in clinical trials and five more agents expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the body’s immune system to combat cancers that includes novel checkpoint inhibitors, chimeric antigen receptor T-cell (CART) technology, myeloid cell targeting agents, and STING agonists. Currently Novartis’ myeloid cell targeting program (MCS-110) and checkpoint inhibitors targeting PD-1 (PDR001), LAG-3 (LAG525), are in phase 1 clinical trials. The CART program (CTL019) is in phase 2 clinical trials. The anti-TIM-3 program (MGB453) is expected to enter the clinic by the end of 2015 and a STING agonist (MIW815), through collaboration with Aduro Biotech, and GITR agonist are progressing toward first-in-human clinical trials in 2016.

The acquisition of Admune adds an IL-15 agonist program currently in phase I clinical trials for metastatic cancer. The licensing agreement with Palobiofarma gives Novartis development and commercialization rights to PBF-509, an adenosine receptor antagonist currently in phase I clinical trials for non-small cell lung cancer. The agreement with XOMA gives Novartis development and commercialization rights to XOMA’s TGF-beta antibody programs. All three programs will be explored as monotherapies and in combination with therapies in Novartis’ immuno-oncology and targeted therapy portfolios.

"The first wave of immuno-oncology therapies has demonstrated the impact this approach can have in treating certain types of tumors, " said Mark Fishman, President of the Novartis Institutes for BioMedical Research. "To realize its full potential requires exploration of the complex system of biological pathways in the tumor microenvironment with agents that can stimulate the immune system to attack a wider variety of tumors."

In pre-clinical studies, IL-15 therapies have been shown to activate CD8+, CD4+ memory T cells and Natural Killer (NK) cells that play a critical role in stimulating the immune system. Adenosine and TGFß both drive immune suppression in the tumor microenvironment, which allows cancer cells to escape immune surveillance, making inhibition of these two pathways an attractive next-generation immuno-oncology approach.